Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 infection diagnosed by nasopharyngeal sample~* Need for supplemental oxygen to maintain oxygen saturation \> 93%~* 12 years of age or older~Exclusion Criteria:~* Neutrophils \< 1 x 10\^9/L~* Platelets \< 50 x 10\^9/L~* Serum total bilirubin \>2.0 x upper limit of normal (ULN)~* Aspartate aminotransferase (AST), or alanine aminotransferase (ALT) \> 5x ULN~* Creatinine clearance (CrCl) \< 15 mL/minute~* Pregnant women~* Known HBV or HIV infection~* Signs and symptoms of Varicella Zoster Virus (VZV) infection~* Patients requiring invasive mechanical ventilation. Patients requiring non-invasive mechanical ventilation (e.g., BiPAP) are eligible.~* Patients who require supplemental oxygen support prior to COVID-19 infection.~* Patients who are on ruxolitinib or similiar drugs.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib to prevent COVID-19 pneumonia (Type: EXPERIMENTAL): All participants will receive ruxolitinib at at 10 mg, twice a day, for 14 days, followed by 5 mg, twice a day, for 2 days and 5 mg, once daily, for 1 day.

Based on this trial design, predict the completion outcome and termination type (if applicable).